Potential examples of such tumor-agnostic targets other than NTRK include (but not limited to) ALK, BRAF, BRCAness, FGFR, HER2, HER3, homologous recombination deficiency (HRD), KRAS, RET, ROS1, tumor mutation burden (TMB) high. Here, KRAS is linked to neoplasm.